Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1458-1464; doi:10.1093/jnci/93.19.1458
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mok, S. C.
Right arrow Articles by Cramer, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mok, S. C.
Right arrow Articles by Cramer, D. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1458-1464, October 3, 2001
© 2001 Oxford University Press

Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology

Samuel C. Mok, Julie Chao, Steven Skates, Kwong-kwok Wong, Gary K. Yiu, Michael G. Muto, Ross S. Berkowitz, Daniel W. Cramer

Affiliations of authors: S. C. Mok, G. K. Yiu, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; J. Chao, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston; S. Skates, Gillette Center for Women's Cancer, Dana-Farber Cancer Institute, and Biostatistics Center, Massachusetts General Hospital, Boston; K. Wong, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston; M. G. Muto, R. S. Berkowitz, D. W. Cramer, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, and Gillette Center for Women's Cancer, Dana-Farber Cancer Institute.

Correspondence to: Samuel C. Mok, Ph.D., Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, 221 Longwood Ave., BLI 449, Boston, MA 02115 (e-mail: scmok{at}rics.bwh.harvard.edu).

Background: Screening biomarkers for ovarian cancer are needed because of its late stage at diagnosis and poor survival. We used microarray technology to identify overexpressed genes for secretory proteins as potential serum biomarkers and selected prostasin, a serine protease normally secreted by the prostate gland, for further study. Methods: RNA was isolated and pooled from three ovarian cancer cell lines and from three normal human ovarian surface epithelial (HOSE) cell lines. Complementary DNA generated from these pools was hybridized to a microarray slide, and genes overexpressed in the cancer cells were identified. Real-time quantitative polymerase chain reaction was used to examine prostasin gene expression in ovarian cancer and HOSE cell lines. Anti-prostasin antibodies were used to examine prostasin expression and to measure serum prostasin by an enzyme-linked immunosorbent assay in 64 case patients with ovarian cancer and in 137 control subjects. Previously determined levels of CA 125, an ovarian cancer marker, were available from about 70% of all subjects. All statistical tests were two-sided. Results: Prostasin was detected by immunostaining more strongly in cancerous ovarian epithelial cells and stroma than in normal ovarian tissue. The mean level of serum prostasin was 13.7 µg/mL (95% confidence interval [CI] = 10.5 to 16.9 µg/mL) in 64 case patients with ovarian cancer and 7.5 µg/mL (95% CI = 6.6 to 8.3 µg/mL) in 137 control subjects (P<.001, after adjustment for the subject's age, year of collection, and specimen quality). In 14 of 16 case patients with both preoperative and postoperative serum samples, postoperative prostasin levels were statistically significantly lower than preoperative levels (P = .004). In 37 case patients with nonmucinous ovarian cancer and in 100 control subjects for whom levels of CA 125 and prostasin were available, the combination of markers gave a sensitivity of 92% (95% CI = 78.1% to 98.3%) and a specificity of 94% (95% CI = 87.4% to 97.7%) for detecting ovarian cancer. Conclusions: Prostasin is overexpressed in epithelial ovarian cancer and should be investigated further as a screening or tumor marker, alone and in combination with CA 125.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Trope and J. Kaern
Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature
J. Clin. Oncol., July 10, 2007; 25(20): 2909 - 2920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al.
An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Netzel-Arnett, B. M. Currie, R. Szabo, C.-Y. Lin, L.-M. Chen, K. X. Chai, T. M. Antalis, T. H. Bugge, and K. List
Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation
J. Biol. Chem., November 3, 2006; 281(44): 32941 - 32945.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. F. Chambers and B. C. Vanderhyden
Ovarian Cancer Biomarkers in Urine
Clin. Cancer Res., January 15, 2006; 12(2): 323 - 327.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Fan, T. D. Wu, W. Li, and D. Kirchhofer
Identification of Hepatocyte Growth Factor Activator Inhibitor-1B as a Potential Physiological Inhibitor of Prostasin
J. Biol. Chem., October 14, 2005; 280(41): 34513 - 34520.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
J. J. Liu, G. Cutler, W. Li, Z. Pan, S. Peng, T. Hoey, L. Chen, and X. B. Ling
Multiclass cancer classification and biomarker discovery using GA-based algorithms
Bioinformatics, June 1, 2005; 21(11): 2691 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Narod and K. Offit
Prevention and Management of Hereditary Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663.
[Full Text] [PDF]

Home page
 JCOHome page
H. Matsuzaki, H. Kobayashi, T. Yagyu, K. Wakahara, T. Kondo, N. Kurita, H. Sekino, K. Inagaki, M. Suzuki, N. Kanayama, et al.
Plasma Bikunin As a Favorable Prognostic Factor in Ovarian Cancer
J. Clin. Oncol., March 1, 2005; 23(7): 1463 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Michael and M.M. Doherty
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zhang, R. C. Bast Jr., Y. Yu, J. Li, L. J. Sokoll, A. J. Rai, J. M. Rosenzweig, B. Cameron, Y. Y. Wang, X.-Y. Meng, et al.
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer
Cancer Res., August 15, 2004; 64(16): 5882 - 5890.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Hibbs, K. M. Skubitz, S. E. Pambuccian, R. C. Casey, K. M. Burleson, T. R. Oegema Jr, J. J. Thiele, S. M. Grindle, R. L. Bliss, and A. P.N. Skubitz
Differential Gene Expression in Ovarian Carcinoma: Identification of Potential Biomarkers
Am. J. Pathol., August 1, 2004; 165(2): 397 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. Sutphen, Y. Xu, G. D. Wilbanks, J. Fiorica, E. C. Grendys Jr., J. P. LaPolla, H. Arango, M. S. Hoffman, M. Martino, K. Wakeley, et al.
Lysophospholipids Are Potential Biomarkers of Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1185 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. O. Schorge, R. D. Drake, H. Lee, S. J. Skates, R. Rajanbabu, D. S. Miller, J.-H. Kim, D. W. Cramer, R. S. Berkowitz, and S. C. Mok
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
Clin. Cancer Res., May 15, 2004; 10(10): 3474 - 3478.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
I. J. Jacobs and U. Menon
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-H. Kim, D. Herlyn, K.-k. Wong, D.-C. Park, J. O. Schorge, K. H. Lu, S. J. Skates, D. W. Cramer, R. S. Berkowitz, and S. C. Mok
Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer
Clin. Cancer Res., October 15, 2003; 9(13): 4782 - 4791.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner
Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis
PNAS, October 14, 2003; 100(21): 12343 - 12348.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. M. Yousef, A. Scorilas, D. Katsaros, S. Fracchioli, L. Iskander, C. Borgono, I. A. Rigault de la Longrais, M. Puopolo, M. Massobrio, and E. P. Diamandis
Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer
J. Clin. Oncol., August 15, 2003; 21(16): 3119 - 3126.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Ye, D. W. Cramer, S. J. Skates, S. P. Gygi, V. Pratomo, L. Fu, N. K. Horick, L. J. Licklider, J. O. Schorge, R. S. Berkowitz, et al.
Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry
Clin. Cancer Res., August 1, 2003; 9(8): 2904 - 2911.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. C. Bast Jr
Status of Tumor Markers in Ovarian Cancer Screening
J. Clin. Oncol., May 15, 2003; 21(90100): 200s - 205.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. G. Baker
The Central Role of Receiver Operating Characteristic (ROC) Curves in Evaluating Tests for the Early Detection of Cancer
J Natl Cancer Inst, April 2, 2003; 95(7): 511 - 515.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Wang, J. Chao, and L. Chao
Adenovirus-mediated human prostasin gene delivery is linked to increased aldosterone production and hypertension in rats
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1031 - R1036.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. B. Welsh, L. M. Sapinoso, S. G. Kern, D. A. Brown, T. Liu, A. R. Bauskin, R. L. Ward, N. J. Hawkins, D. I. Quinn, P. J. Russell, et al.
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum
PNAS, March 18, 2003; 100(6): 3410 - 3415.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Diamandis, A. Scorilas, S. Fracchioli, M. van Gramberen, H. de Bruijn, A. Henrik, A. Soosaipillai, L. Grass, G. M. Yousef, U.-H. Stenman, et al.
Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma
J. Clin. Oncol., March 15, 2003; 21(6): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L.-Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Bellino, M. van Gramberen, H. de Bruijn, A. Henrik, U.-H. Stenman, M. Massobrio, et al.
The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis
Cancer Res., February 15, 2003; 63(4): 807 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle
Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 103 - 113.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. C. Young
Early-Stage Ovarian Cancer: To Treat or Not To Treat
J Natl Cancer Inst, January 15, 2003; 95(2): 94 - 95.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. F. Macgregor and J. A. Squire
Application of Microarrays to the Analysis of Gene Expression in Cancer
Clin. Chem., August 1, 2002; 48(8): 1170 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kuramoto, K. Morimura, S. Yamashita, E. Okochi, N. Watanabe, T. Ohta, M. Ohki, S. Fukushima, T. Sugimura, and T. Ushijima
Etiology-specific Gene Expression Profiles in Rat Mammary Carcinomas
Cancer Res., July 1, 2002; 62(13): 3592 - 3597.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. O'Regan, C. Fleming, J. D. Seidman, R. C. Wallach, S. C. Mok, S. J. Skates, R. S. Berkowitz, and D. W. Cramer
Osteopontin as a Biomarker for Ovarian Cancer
JAMA, June 26, 2002; 287(24): 3208 - 3210.
[Full Text] [PDF]

Home page
 JAMAHome page
J.-H. Kim, S. J. Skates, T. Uede, K.-k. Wong, J. O. Schorge, C. M. Feltmate, R. S. Berkowitz, D. W. Cramer, and S. C. Mok
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
JAMA, April 3, 2002; 287(13): 1671 - 1679.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. B. Mills, R. C. Bast Jr., and S. Srivastava
Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics
J Natl Cancer Inst, October 3, 2001; 93(19): 1437 - 1439.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.